Stock of the Day

Today's Trend

89BIO (NASDAQ: ETNB) shares rallied on news that Roche agreed to acquire the clinical‐stage biotech for $14.50 per share in cash plus up to $6.00 in contingent value rights, driving the stock to a new 52‐week high. Later, shares gave back some gains as law firms launched investigations into the sale process and analysts adjusted ratings.

• Roche agreed to acquire 89BIO for $2.4 billion upfront ($14.50 per share) plus up to $6.00 in CVRs, representing a total equity value of up to $3.5 billion and a ~79% premium to the pre‐announcement price. Roche to acquire liver drug developer 89bio for up to $3.5 billion
• The stock soared 86% to a historic high on the merger news and hit a new 52-week high, prompting some bullish commentary on buying the dip. 89Bio (ETNB) Soars 86% to Historic High
• 89BIO officially announced the merger agreement in a Business Wire release, detailing the tender offer structure, CVR milestones, and closing conditions expected in Q4 2025. Shareholder Alert: The Ademi Firm Investigates Whether 89bio, Inc. is Obtaining a Fair Price
• Multiple law firms (Kahn Swick & Foti, Halper Sadeh, The Ademi Firm) have launched investigations into whether the $14.50 per‐share offer and sale process are fair to shareholders. 89BIO INVESTOR ALERT by the Former Attorney General of Louisiana
• Analysts have trimmed expectations: Raymond James cut ETNB to “Market Perform,” Wolfe Research downgraded to “Peer Perform,” and HC Wainwright reaffirmed a neutral rating with a $14.50 price target (2.5% downside). Raymond James cuts 89bio to “market perform”